Aquestive Therapeutics (AQST) Aandelenoverzicht
Aquestive Therapeutics, Inc. is actief als farmaceutisch bedrijf in de Verenigde Staten en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 2/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
AQST Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Aquestive Therapeutics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$4.18 |
| 52 Week Hoogtepunt | US$7.55 |
| 52 Week Laag | US$2.93 |
| Bèta | 1.45 |
| 1 maand verandering | 6.36% |
| 3 maanden verandering | 1.21% |
| 1 Jaar Verandering | 12.97% |
| 3 jaar verandering | 153.33% |
| 5 jaar verandering | 10.88% |
| Verandering sinds IPO | -73.96% |
Recent nieuws en updates
Narratiefupdate • Jun 22
AQST: FDA Alignment On 2026 Resubmission Will Support Bullish Outlook
Analysts have modestly adjusted their price target for Aquestive Therapeutics to $6.15, citing updated expectations for revenue growth, profit margins, and future P/E assumptions reflected in recent Street research. What's in the News Aquestive Therapeutics reaffirmed earnings guidance for the full year 2026, with expected total revenue in a range of US$46 million to US$50 million.Narratiefupdate • Jun 08
AQST: FDA Feedback And 2026 Resubmission Will Drive Long Term Upside
Analysts have reaffirmed a constructive view on Aquestive Therapeutics, nudging their price target higher to $6.15. This view is supported by updated assumptions on revenue growth, profit margins and future P/E that keep the stock aligned with their Outperform thesis.Seeking Alpha • Jun 04
Aquestive Therapeutics: Rating Downgrade Despite Probability Of Anaphylm Approval
Summary Aquestive Therapeutics is downgraded to Hold after the FDA issued a Complete Response Letter for Anaphylm, citing human factors study deficiencies. Management plans to resubmit the Anaphylm NDA in Q3 2026, aiming for potential US, EU, UK, and Canada approvals by the end of 2027 if data satisfy regulators. AQST’s strong cash position and new $150M Oaktree debt facility extend the runway through a potential Anaphylm launch, but profitability concerns persist. Competition from needle-free alternatives, expiring EpiPen patents, and uncertain real-world adoption temper confidence in Anaphylm’s $300–400M peak sales potential. Read the full article on Seeking AlphaRecent updates
Narratiefupdate • Jun 22
AQST: FDA Alignment On 2026 Resubmission Will Support Bullish Outlook
Analysts have modestly adjusted their price target for Aquestive Therapeutics to $6.15, citing updated expectations for revenue growth, profit margins, and future P/E assumptions reflected in recent Street research. What's in the News Aquestive Therapeutics reaffirmed earnings guidance for the full year 2026, with expected total revenue in a range of US$46 million to US$50 million.Narratiefupdate • Jun 08
AQST: FDA Feedback And 2026 Resubmission Will Drive Long Term Upside
Analysts have reaffirmed a constructive view on Aquestive Therapeutics, nudging their price target higher to $6.15. This view is supported by updated assumptions on revenue growth, profit margins and future P/E that keep the stock aligned with their Outperform thesis.Seeking Alpha • Jun 04
Aquestive Therapeutics: Rating Downgrade Despite Probability Of Anaphylm Approval
Summary Aquestive Therapeutics is downgraded to Hold after the FDA issued a Complete Response Letter for Anaphylm, citing human factors study deficiencies. Management plans to resubmit the Anaphylm NDA in Q3 2026, aiming for potential US, EU, UK, and Canada approvals by the end of 2027 if data satisfy regulators. AQST’s strong cash position and new $150M Oaktree debt facility extend the runway through a potential Anaphylm launch, but profitability concerns persist. Competition from needle-free alternatives, expiring EpiPen patents, and uncertain real-world adoption temper confidence in Anaphylm’s $300–400M peak sales potential. Read the full article on Seeking Alpha
Narratiefupdate • May 25
AQST: 2026 NDA Resubmission Will Drive Allergy Treatment Upside Potential
Analysts have kept their fair value estimate for Aquestive Therapeutics steady at $11.00 while lowering near term growth and margin assumptions. Alongside a recent cut in one firm’s price target to $9.00 that breaks out Anaphylm, Libervant, other assets and net cash, they are focusing more on product specific drivers and regulatory timing than on broad multiple expansion.Narratiefupdate • May 02
AQST: FDA CRL Resolution And 2026 Resubmission Will Drive Long Term Upside
Analysts have trimmed their average price targets for Aquestive Therapeutics, with recent cuts such as Alliance Global's move to $9 from $12. These changes reflect updated views on Anaphylm's regulatory path and on the value of the broader pipeline and cash position.Narratiefupdate • Apr 17
AQST: FDA Anaphylaxis Film Resubmission Timeline Will Shape Long Term Upside
Analysts have reduced their price targets for Aquestive Therapeutics to $9 per share, reflecting updated views on the timing and value contribution of Anaphylm, Libervant, and the company’s manufacturing and licensing assets following the recent FDA Complete Response Letter. Analyst Commentary Street research commentary around Aquestive Therapeutics has turned more cautious following the FDA Complete Response Letter for Anaphylm and the subsequent revision of expectations for the company’s product portfolio and assets.Narratiefupdate • Apr 02
AQST: Regulatory Delay And 2026 Resubmission Will Ultimately Catalyze Allergy Treatment Upside
Analysts trimmed their price targets on Aquestive Therapeutics to around $9 per share. This reflects a reassessment of timing and risk after the FDA's Complete Response Letter on Anaphylm, even as they continue to ascribe value to Anaphylm, Libervant, existing manufacturing and royalty streams, and net cash.Narratiefupdate • Mar 19
AQST: Regulatory Setbacks Will Ultimately Catalyze Future Allergy Treatment Upside
Aquestive Therapeutics' fair value estimate has been revised to $11.00 from $12.00 as analysts factor in updated assumptions around Anaphylm's regulatory timing and asset-level contributions following recent price target cuts and detailed sum of the parts analysis. Analyst Commentary Bullish analysts are reframing Aquestive Therapeutics primarily around the potential of Anaphylm, with updated fair value work that parses the business into distinct asset contributions.Narratiefupdate • Mar 05
AQST: FDA Feedback Will Delay Allergy Film Yet Preserve Long Term Upside
Narrative Update The Street has trimmed its average price target on Aquestive Therapeutics by $2, as analysts factor in the recent complete response letter on Anaphylm as a delay. They still view this delay as coming with a clearly defined, fixable path to a future approval decision.Narratiefupdate • Feb 19
AQST: Regulatory Clarity On Allergy Treatment Will Drive Future Upside Potential
Aquestive Therapeutics' analyst price target has shifted from $14.49 to $12.00 as analysts factor in the recent complete response letter for Anaphylm, a modestly higher discount rate, and recalibrated assumptions for revenue growth, profit margin, and a higher future P/E multiple reflecting updated views on the regulatory path and risk profile. Analyst Commentary Bullish analysts acknowledge the complete response letter for Anaphylm as a key setback, but several see it as a definable regulatory event rather than a permanent roadblock.Analyseartikel • Feb 05
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely
Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shareholders that were waiting for something to happen have been dealt a...Narratiefupdate • Feb 05
AQST: FDA Letters Create Delay Yet Future Allergy Franchise Upside Remains
Analysts have revised their fair value estimate for Aquestive Therapeutics from US$7.00 to US$6.00, citing reduced revenue growth assumptions and a slightly lower future P/E multiple following recent FDA communications and updated Street research on Anaphylm. Analyst Commentary Recent Street research around Anaphylm and the FDA feedback has led several bearish analysts to revisit their models and risk assumptions for Aquestive Therapeutics.Analyseartikel • Feb 04
Need To Know: The Consensus Just Cut Its Aquestive Therapeutics, Inc. (NASDAQ:AQST) Estimates For 2026
One thing we could say about the analysts on Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) - they aren't optimistic...Narratiefupdate • Jan 21
AQST: FDA Review Setback Will Still Support Long Term Allergy Franchise Upside
Narrative Update Analysts have trimmed their fair value estimate for Aquestive Therapeutics to US$7.00, citing the recent FDA deficiency letter on Anaphylm and a higher chance of a complete response letter that could delay potential market entry. Analyst Commentary Recent commentary from bearish analysts has focused on the regulatory setback for Anaphylm and its potential impact on Aquestive Therapeutics' valuation and execution risk.Narratiefupdate • Jan 07
AQST: New Patents Will Extend Allergy Franchise Exclusivity And Support Future Upside
Analysts have lifted their price target on Aquestive Therapeutics to $12 from $9, citing new Anaphylm patents that extend brand exclusivity through at least 2037 and are viewed as meaningfully value accretive to the franchise. Analyst Commentary Recent research has centered on the new Anaphylm patents and what they might mean for Aquestive Therapeutics’ long term value.Narratiefupdate • Dec 21
AQST: New Patents Will Extend Key Allergy Franchise Exclusivity Through 2037
Analysts have raised their price target on Aquestive Therapeutics to $12 from $9, reflecting a higher fair value estimate of about $8 per share as they factor in stronger projected revenue growth, modestly higher risk assumptions, and the value of new patents extending Anaphylm exclusivity through at least 2037. Analyst Commentary While the latest price target increase reflects growing confidence in Aquestive Therapeutics' long term prospects, it also raises the bar for execution.
Narratiefupdate • Dec 07
AQST: Extended Patent Protection Will Support Future Share Price Outperformance
Analysts nudged their price targets on Aquestive Therapeutics higher by roughly $3 to $12, citing newly issued patents that extend Anaphylm's exclusivity through at least 2037 and growing confidence in FDA approval prospects following the decision not to convene an advisory committee for the NDA. Analyst Commentary Street research has turned increasingly constructive on Aquestive Therapeutics as recent developments around Anaphylm have prompted upward revisions to valuation models and a reassessment of execution risk.Narratiefupdate • Nov 23
AQST: Multiple Patent Wins And Regulatory Progress Will Support Continued Share Price Outperformance
Analysts have raised their fair value estimate for Aquestive Therapeutics from $9.08 to $10.30. This change reflects recent patent wins for Anaphylm and improved regulatory outlooks, which are expected to enhance long-term growth and exclusivity for the company.Analyseartikel • Nov 15
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shares have retraced a considerable 27% in the last month, reversing a...Narratiefupdate • Nov 07
AQST: Extended Patent Protection Will Drive Sustained Share Price Upside
Analysts have recently raised their price targets for Aquestive Therapeutics, with notable increases from $7 to $8 and from $9 to $12. They cite strengthened patent protection for Anaphylm and a smoother regulatory pathway as key drivers behind their more optimistic outlook.Narratiefupdate • Oct 24
Patent Extensions and FDA Momentum Will Support Upcoming Needle-Free Epinephrine Launch
Analysts have recently raised their price targets for Aquestive Therapeutics, with increases up to $12 per share. They cite extended patent protection for Anaphylm and positive regulatory developments as key factors supporting a more optimistic outlook.Narratiefupdate • Oct 09
Upcoming FDA Approval Will Enable Needle-Free Epinephrine Adoption
The analyst fair value estimate for Aquestive Therapeutics has been increased by $0.50 to $9.08. Analysts cite recent patent extensions and regulatory progress for Anaphylm as key drivers of the upward revision.Analyseartikel • Sep 05
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shares have continued their recent momentum with a 28% gain in the last...Analyseartikel • Aug 14
Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts
NasdaqGM:AQST 1 Year Share Price vs Fair Value Explore Aquestive Therapeutics's Fair Values from the Community and...Analyseartikel • Jul 21
After Leaping 29% Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Are Not Flying Under The Radar
Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shares have continued their recent momentum with a 29% gain in the last...Analyseartikel • May 16
Analysts Have Lowered Expectations For Aquestive Therapeutics, Inc. (NASDAQ:AQST) After Its Latest Results
The analysts might have been a bit too bullish on Aquestive Therapeutics, Inc. ( NASDAQ:AQST ), given that the company...
Nieuw narratief • Mar 31
FDA Approval And Anaphylm Launch Will Expand Global Reach
Success in FDA approval for Anaphylm and Libervant expansion could significantly boost revenue and market penetration.Analyseartikel • Mar 21
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) P/S Is On The Mark
When close to half the companies in the Pharmaceuticals industry in the United States have price-to-sales ratios (or...Seeking Alpha • Jan 06
Aquestive Therapeutics: Five Foci For 2025
Summary Aquestive Therapeutics' Anaphylm is nearing FDA approval, potentially disrupting the U.S. anaphylaxis market dominated by EpiPen, with peak sales estimated at $300–400M. AQST-108, a topical epinephrine gel for alopecia areata, shows promise with minimal side effects and could expedite its regulatory path, targeting a billion-dollar market. Libervant, a diazepam buccal film for cluster seizures, has gained orphan drug exclusivity, extending market exclusivity to 2031, ensuring a reliable revenue stream. Investors should monitor Aquestive's cash burn, partnerships, and earnings closely, as positive outcomes could significantly boost revenue, despite potential regulatory and commercial risks. I discuss my game plan for restarting my accumulation of AQST. Read the full article on Seeking AlphaAnalyseartikel • Dec 19
The Price Is Right For Aquestive Therapeutics, Inc. (NASDAQ:AQST) Even After Diving 25%
Unfortunately for some shareholders, the Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) share price has dived 25% in the...Seeking Alpha • Nov 05
Aquestive: Rare Opportunity With Dual Platform Strategy
Summary Aquestive Therapeutics specializes in innovative film-based medicines and epinephrine products & delivery. The company's PharmFilm and Adrenaverse platforms offer unique competitive advantages, making it a strong investment opportunity. A risk-adjusted valuation indicates that Aquestive is currently undervalued compared to its market price. Understanding the fundamentals of competitive strategy highlights how Aquestive's platforms create sustainable economic moats. Read the full article on Seeking AlphaAnalyseartikel • Sep 07
Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher
Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shares have continued their recent momentum with a 27% gain in the last...Seeking Alpha • Aug 20
Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025
Summary Aquestive Therapeutics shares surged 137.29% (YoY) after FDA approval of rival company ARS Pharmaceutical's "epinephrine nasal spray" Neffy. Market optimism surrounds AQST’s robust R&D pipeline, with analysts giving outperform rating and price target increase to $15. AQST recorded significant revenue growth in Q2 2024, with a cash balance of $89.87 million and sufficient funds until the end of 2026. Read the full article on Seeking AlphaAnalyseartikel • Aug 11
Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic
Celebrations may be in order for Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shareholders, with the analysts...Analyseartikel • Jul 24
What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You
Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shareholders are no doubt pleased to see that the share price has bounced...Analyseartikel • May 22
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shares have retraced a considerable 27% in the last month, reversing a...Seeking Alpha • Apr 09
Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
Summary Aquestive Therapeutics has achieved positive Phase III data for their Anaphylm epinephrine sublingual film, showing comparable efficacy to auto-injectors. The company is moving forward with plans to file a New Drug Application (NDA) and has several upcoming catalysts, including self-administration and allergen studies. Anaphylm has the potential to disrupt the market dominated by auto-injectors, with global peak sales projected to surpass $1 billion. Read the full article on Seeking AlphaAnalyseartikel • Feb 28
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up
Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shares have continued their recent momentum with a 30% gain in the last...Seeking Alpha • Jan 19
Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1
Summary Aquestive Therapeutics is nearing a key topline readout for its Anaphylm sublingual film, a potential groundbreaking oral epinephrine treatment for severe allergic reactions. If the data is positive, Anaphylm could be heading for a possible New Drug Application in 2024, with a potential commercial launch in 2025. Aquestive faces risks from regulatory hurdles, competition from other epinephrine treatments, and potential financial setbacks. Read the full article on Seeking AlphaRendement voor aandeelhouders
| AQST | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 0.5% | 1.4% | 1.6% |
| 1Y | 13.0% | 48.6% | 18.6% |
Rendement versus industrie: AQST presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 48.6 % opleverde.
Rendement versus markt: AQST presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 18.6 % opleverde.
Prijsvolatiliteit
| AQST volatility | |
|---|---|
| AQST Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: AQST heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van AQST is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2004 | 147 | Dan Barber | www.aquestive.com |
Aquestive Therapeutics, Inc. is actief als farmaceutisch bedrijf in de Verenigde Staten en internationaal. Het biedt Libervant aan, een buccale oplosbare filmformulering van diazepam voor de behandeling van aanvallen; Suboxone, een sublinguale filmformulering van buprenorfine en naloxon voor de behandeling van opioïde afhankelijkheid; EMYLIF, een orale filmformulering van riluzol; ONDIF, een orale oplosbare filmformulering van ondansetron; SYMPAZAN, een orale oplosbare filmformulering van clobazam gebruikt voor de behandeling van aanvallen geassocieerd met een zeldzame, hardnekkige vorm van epilepsie; KYNMOBI, een sublinguale filmformulering van apomorfine; en AZSTARYS, een door de FDA goedgekeurd, eenmaal daags product voor de behandeling van ADHD bij patiënten van 6 jaar en ouder. De eigen pijplijnproducten van het bedrijf omvatten Anaphylm, een epinefrine-sublinguale film, die zich in fase 3 van het klinisch onderzoek bevindt voor de noodbehandeling van allergische reacties, waaronder anafylaxie; en AQST-108, een topische gel die zich in fase 2 van het klinisch onderzoek bevindt voor de behandeling van alopecia areata.
Aquestive Therapeutics, Inc. Samenvatting
| AQST fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$524.38m |
| Inkomsten(TTM) | -US$68.91m |
| Inkomsten(TTM) | US$50.27m |
10.4x
P/S-verhouding-7.6x
Koers/WinstverhoudingIs AQST overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| AQST resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$50.27m |
| Kosten van inkomsten | US$18.37m |
| Brutowinst | US$31.90m |
| Overige uitgaven | US$100.81m |
| Inkomsten | -US$68.91m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.55 |
| Brutomarge | 63.45% |
| Nettowinstmarge | -137.08% |
| Schuld/Eigen Vermogen Verhouding | -113.5% |
Hoe presteerde AQST op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/06 20:33 |
| Aandelenkoers aan het einde van de dag | 2026/07/02 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Aquestive Therapeutics, Inc. wordt gevolgd door 13 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| James Molloy | Alliance Global Partners |
| Gary Nachman | BMO Capital Markets Equity Research |
| Kristen Kluska | Cantor Fitzgerald & Co. |